| Assessment of the effect of DMARD use on the mortality of patients with rheumatoid arthritis | Mehmet Ali BALCI, Lütfi AKYOL | 58–65 |
| Relationship between antibodies and clinical manifestations in systemic lupus erythematosus | Reyhan BİLİCİ SALMAN, Seminur HAZNEDAROĞLU | 66–73 |
| Comparison of cranial and extra-cranial involvement of patients with giant cell arteritis | Andaç KOMAÇ, Özlem ÖZDEMİR IŞIK, Ayten YAZICI, Ayşe ÇEFLE | 74–80 |
| Sleep quality and its association with disease activity, depression and quality of life in Behçet’s disease patients | Özge POLAT KORKMAZ, Aysun AKSOY, Birkan İLHAN, Fatma ALİBAZ ÖNER, Haner DİRESKENELİ | 81–86 |
| Predicting the response to bDMARD treatment in RA: Then what? | Ceren TUNCER SAKAR, Gülşah KARAKAYA, Emre BİLGİN, Levent KILIÇ, Umut KALYONCU | 87–93 |
| The effect of MEFV gene mutations on the clinical course of PFAPA syndrome | Nilüfer TEKGÖZ, Zahide EKİCİ TEKİN, Elif ÇELİKEL, Fatma AYDIN, Tuba KURT, Müge SEZER, Cüneyt KARAGÖL, Serkan COŞKUN, Melike Mehveş KAPLAN, Merve Cansu POLAT, Nimet ÖNER, Banu ACAR | 94–99 |
| Serum amyloid A may be a potential biomarker for vasculitis | Hakan BABAOĞLU | 100–105 |
| CPPD-related pseudoneuroarthropathy in a patient with myelodysplastic syndrome | Mete PEKDİKER, Gezmiş KİMYON | 106–109 |
| Anti-Jo-1 associated disease after inactive COVID-19 vaccine | Zeliha ADEMOĞLU, Kübra EROL KALKAN, Ufuk İLGEN, Hakan EMMUNGİL | 110–111 |